fcgr2a-protein

fcgr2a-protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FC Gamma Receptor IIA</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>FCGR2A</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P08575" target="_blank">P08575</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/1T8M" target="_blank">1T8M</a></td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>34 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cell membrane (immune cells)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Ig superfamily</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/alzheimers">Alzheimer's Disease</a>, Neuroinflammation</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>

FC Gamma Receptor IIA

Overview

FC Gamma Receptor IIA is a protein encoded by the FCGR2A gene. It belongs to the Ig superfamily family and has a molecular weight of approximately 34 kDa. This protein is localized to Cell membrane (immune cells) and plays a significant role in the pathogenesis of [Alzheimer's Disease](/diseases/alzheimers-disease), Neuroinflammation.

Structure

FC Gamma Receptor IIA has been characterized structurally through X-ray crystallography and cryo-EM. Available PDB structures include: [1T8M](https://www.rcsb.org/structure/1T8M).

fcgr2a-protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FC Gamma Receptor IIA</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>FCGR2A</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P08575" target="_blank">P08575</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/1T8M" target="_blank">1T8M</a></td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>34 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cell membrane (immune cells)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Ig superfamily</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/alzheimers">Alzheimer's Disease</a>, Neuroinflammation</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>

FC Gamma Receptor IIA

Overview

FC Gamma Receptor IIA is a protein encoded by the FCGR2A gene. It belongs to the Ig superfamily family and has a molecular weight of approximately 34 kDa. This protein is localized to Cell membrane (immune cells) and plays a significant role in the pathogenesis of [Alzheimer's Disease](/diseases/alzheimers-disease), Neuroinflammation.

Structure

FC Gamma Receptor IIA has been characterized structurally through X-ray crystallography and cryo-EM. Available PDB structures include: [1T8M](https://www.rcsb.org/structure/1T8M).

The protein's three-dimensional structure can also be explored via the [AlphaFold Protein Structure Database](https://alphafold.ebi.ac.uk/entry/P08575).

Normal Function

Under physiological conditions, FC Gamma Receptor IIA performs essential functions in the nervous system. It is primarily found in Cell membrane (immune cells) and contributes to normal cellular homeostasis, signaling, and neuronal function.

Role in Disease

FC Gamma Receptor IIA is implicated in the following neurodegenerative conditions:

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)

Therapeutic Targeting

FC Gamma Receptor IIA represents an important therapeutic target. Multiple drug development programs are exploring strategies to modulate its function, reduce toxic forms, or enhance clearance mechanisms.

Key Publications

External Links

• UniProt: [https://www.uniprot.org/uniprot/P08575](https://www.uniprot.org/uniprot/P08575)
• AlphaFold: [FC Gamma Receptor IIA](https://alphafold.ebi.ac.uk/entry/P08575)
• PDB: [1T8M](https://www.rcsb.org/structure/1T8M)

Fc Receptor Biology

Receptor Classification

The Fc gamma receptor family comprises several activation and inhibitory receptors that mediate immune complex signaling[@raves2010]:

• FCGR1 (CD64): High-affinity IgG receptor, primarily on monocytes/macrophages
• FCGR2A (CD32): Low-affinity activating receptor, broad immune cell expression
• FCGR2B (CD32B): The sole inhibitory FcγR, regulates immune responses
• FCGR3A (CD16): Low-affinity activating receptor, on NK cells and macrophages
• FCGR3B (CD16B): GPI-anchored form, on neutrophils

Signaling Mechanisms

ITAM-Mediated Activation
FCGR2A signaling proceeds through its associated FcR γ-chain or via direct ITAM phosphorylation[@genoud2018]:

Negative Regulation
FCGR2A activity is regulated by:

• Co-engagement with FCGR2B (inhibitory receptor)
• SHIP hydrolysis of PI(3,4,5)P3
• Receptor internalization and degradation

Role in Microglial Function

Microglial Phagocytosis

Microglia are the brain's resident macrophages and rely heavily on FcγRs for phagocytic clearance[@walker2019]. In Alzheimer's disease:

Amyloid Clearance: Microglial FCGR2A mediates phagocytosis of opsonized amyloid-beta plaques[@hong2016]. IgG antibodies against Aβ bind to FCGR2A, triggering microglial phagocytosis. This mechanism is thought to contribute to both beneficial plaque clearance and pathological inflammatory responses.

Synaptic Pruning: During development, microglia use complement and Fc receptors to prune excess synapses. In AD, this process may become dysregulated, contributing to synaptic loss.

Neuroinflammatory Modulation

FCGR2A on microglia mediates pro-inflammatory responses to immune complexes[@tazir2015]:

• Cytokine production: IL-1β, TNF-α, IL-6 release
• Reactive oxygen species: NADPH oxidase activation
• Nitric oxide synthase: Inducible NO production
• Chemokine secretion: Recruitment of peripheral immune cells

Genetic Associations

FCGR2A Polymorphisms

Several FCGR2A polymorphisms affect receptor function and AD risk[@daniels2016]:

R134R (rs1801274)
A nonsynonymous SNP resulting in histidine at position 131. The His variant shows higher affinity for certain IgG subclasses and is associated with increased AD risk in some populations.

Q27W (rs10800456)
Affects receptor expression levels. The W variant correlates with higher FCGR2A density on microglia.

Genetic Findings

Genome-wide association studies have identified FCGR2A variants influencing AD risk[@fcgra2014]:

• Multiple independent signals in the FCGR locus
• Pleiotropic effects on autoimmune disease risk
• Interactions with complement receptor genes

Therapeutic Targeting

Antibody-Based Therapies

Monoclonal Antibodies
Therapeutic antibodies for AD (aducanumab, lecanemab, donanemab) engage FcγR-mediated effector functions on microglia[@masliah2011]:

• Peripheral sink mechanisms
• Microglial activation via FCGR2A
• Amyloid clearance through opsonization

Small Molecule Modulators

FCGR2A-selective modulators:

• Tyrosine kinase inhibitors reduce downstream signaling
• PI3K inhibitors block phagocytosis
• Syk inhibitors prevent ITAM signaling

Genetic Approaches

• Antisense oligonucleotides targeting FCGR2A
• CRISPR-based FCGR2B overexpression
• Gene editing to enhance FCGR2B expression

Fc Receptor in Disease Mechanisms

Amyloid Clearance vs. Inflammation

The dual role of FCGR2A in AD presents a therapeutic paradox[@ham2019]:

Beneficial clearance: FCGR2A-mediated phagocytosis can clear amyloid deposits when properly engaged.

Pathological inflammation: Excessive FCGR2A signaling drives chronic neuroinflammation.

Therapeutic strategies must balance these opposing functions.

Immune Complex Pathologies

In AD brain, immune complexes accumulate and may propagate pathology[@wilson2013]:

• Anti-Aβ antibodies form complexes with deposited amyloid
• These complexes activate microglia via FCGR2A
• Chronic activation leads to inflammatory neurodegeneration

Microglial Subtypes

FCGR2A Expression Patterns

Microglial FCGR2A expression varies with brain region and disease state[@fuller2014]:

Homeostatic microglia: Low FCGR2A expression in healthy brain

Disease-associated microglia (DAM): Upregulated FCGR2A in AD, PD

Ramos/LPS-licensed microglia: Maximally upregulated FCGR2A with IFN-γ priming

The FCGR2Ahigh microglia represent a pro-inflammatory subtype associated with neurodegeneration.

Marker Relationships

FCGR2A colocalizes with other microglial disease markers:

• P2RY12: Homeostatic marker lost in DAM
• CD68: Phagocytic marker overlapping with FCGR2A
• TREM2: Triggering receptor colocalizes in DAM
• APOE: Lipid metabolism gene modifying FCGR2A function

Therapeutic Development

Clinical Approaches

Anti-FCGR2B antibodies: Enhancing inhibitory signaling

FCGR2A antagonists: Blocking excessive activation

Syk inhibitors: Downstream signaling blockers

Biomarker Applications

FCGR2A as biomarker:

• CSF FCGR2A levels reflect microglial activation
• PET ligands for FCGR2A in development
• Genetic stratification for clinical trials

Fc Receptor Biology in Detail

Receptor Structure-Function Relationships

Extracellular Domain
The extracellular domain of FCGR2A contains two Ig-like domains (D1 and D2) that form the ligand-binding site for IgG Fc regions[@raves2010]. The binding site is located at the membrane-distal tip of the receptor, accessible to IgG in immune complexes. Mutations in this region can affect IgG subclass selectivity.

Transmembrane Region
FCGR2A has a single transmembrane helix. In some splice variants, this region can be skipped, generating a soluble form. The transmembrane region also associates with the FcR γ-chain for signaling.

Cytoplasmic Tail
The cytoplasmic tail contains an ITAM motif (YXXL/I) for activating signaling. This motif is phosphorylated by Src family kinases upon receptor cross-linking.

Fc Receptor Signaling Networks

Immediate Signaling Events
Following immune complex engagement:

Downstream Effectors

• MAPK pathways: ERK, JNK, p38 activation
• Transcription factors: NFAT, AP-1, NF-κB
• Cytoskeletal remodeling: Rac, Cdc42, Rho

Regulation of Fc Receptor Signaling

Feedback Inhibition
FCGR2A signaling is shaped by multiple inhibitory mechanisms:

• FCGR2B co-engagement: The inhibitory receptor reduces activation
• SOCS proteins: Suppress cytokine signaling
• phosphatases: SHP-1, SHP-2 dephosphorylate ITAMs

• Limits duration of signaling
• Delivers immune complexes for degradation
• Enables antigen presentation

Immune Complex Formation in AD

In Alzheimer's disease brain, immune complexes accumulate through multiple mechanisms[@wilson2013]:

Autoantibody Production

• Anti-Aβ antibodies form complexes with deposited amyloid
• Anti-tau antibodies can also form complexes
• These complexes are recognized by FcγRs

• Soluble IgG crosses the BBB via FcRn
• Binds to deposited amyloid in brain
• Triggers microglial activation

Microglial Activation States

Homeostatic Microglia

In the healthy brain, microglia maintain surveillance behavior with minimal FCGR2A expression:

• Ramified morphology with constantly moving processes
• Low expression of activation markers
• High expression of P2RY12 (homeostatic marker)
• Complement-mediated synaptic pruning

Disease-Associated Microglia (DAM)

In AD, microglia transition to DAM states with altered FCGR2A expression:

DAM Stage 1 (early):

• Upregulated FCGR2A
• Increased CD68 (phagocytic marker)
• Loss of P2RY12

• Maximally increased FCGR2A
• Upregulated TREM2
• Pro-inflammatory cytokine production

Interferon-Licensed Microglia

IFN-γ priming further enhances FCGR2A:

• "Super-activated" state
• Enhanced antigen presentation
• More aggressive phagocytosis
• Stronger inflammatory responses

Therapeutic Approaches

Clinical Trial Strategies

FcγR-Targeting Antibodies

• FCGR2B agonists: Enhance inhibitory signaling
• Blocking antibodies: Prevent excessive activation

• Syk inhibitors: Block downstream signaling ( fostamatinib approved for ITP)
• PI3Kδ inhibitors: Reduce phagocytosis
• JAK inhibitors: Block cytokine production

• CAR-T cells: Engineered cells lacking FCGR2A
• Gene editing: Reduce FCGR2A expression

Biomarker Development

Diagnostic biomarkers:

• CSF FCGR2A levels in AD vs. controls
• PET ligands for activated microglia
• Genetic stratification by FCGR2A variants

• FCGR2A expression predicts progression
• Therapy response markers

Cross-links

• [FCGR2A Gene](/genes/fcgr2a)
• [FCGR3A Protein](/proteins/fcgr3a-protein)
• [Microglia](/cell-types/microglia)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Clearance](/mechanisms/amyloid-clearance)

See Also

• [Proteins Index](/proteins)
• [Genes Index](/genes)
• [Diseases Index](/diseases)
• [Mechanisms Index](/mechanisms)
• [Cell Types Index](/cell-types)

Structural Biology

Extracellular Domain Structure

The extracellular region of FCGR2A consists of two immunoglobulin-like domains that form the ligand-binding interface for IgG Fc regions[@pdb]. The D1 domain (membrane-proximal) and D2 domain (membrane-distal) together create a binding pocket that shows differential affinity for IgG subclasses:

• IgG1: Highest affinity binding
• IgG3: High affinity, variable hinge length
• IgG4: Lower affinity
• IgG2: Minimal binding to FCGR2A

Transmembrane and Cytoplasmic Regions

The transmembrane domain serves as a rigid anchor and platform for association with the FcR γ-chain. The cytoplasmic tail contains an immunoreceptor tyrosine-based activation motif (ITAM) with the consensus sequence YXXL/I:

• Y: Tyrosine phosphorylation site
• X: Any amino acid
• L/I: Leucine/isoleucine hydrophobic residue

Signaling Cascades

Primary Signaling Pathways

FCGR2A activation triggers multiple downstream signaling cascades:

Secondary Messenger Systems

Phospholipase C Gamma (PLCγ)

• Hydrolyzes PIP2 to IP3 and DAG
• IP3 triggers calcium release from ER
• DAG activates PKC isoforms
• Results in cytoskeletal remodeling and gene transcription

• Generates PIP3 from PIP2
• Recruits PH-domain proteins to membrane
• Activates AKT/PKB pathway
• Promotes cell survival and phagocytosis

Negative Regulation Mechanisms

FCGR2A signaling is tightly controlled:

Phosphatases

• SHP-1 dephosphorylates ITAM and Syk
• SHIP hydrolyzes PIP3
• PTEN counters PI3K signaling

• FCGR2B co-engagement recruits phosphatases
• CD300a provides inhibitory signals
• Siglecs sialylate to provide self-recognition

Immunoglobulin Subclass Specificity

IgG Subclass Binding Profiles

FCGR2A shows distinct binding preferences[@bick2015]:

| IgG Subclass | Affinity | effector Functions |
|--------------|----------|-------------------|
| IgG1 | High | Phagocytosis, ADCC |
| IgG2 | Low | Minimal |
| IgG3 | High | All functions |
| IgG4 | Moderate | ADCC |

Therapeutic antibodies are often engineered to enhance or reduce FCGR2A engagement.

Fc Engineering

Antibody engineering can modulate FCGR2A interactions:

• Effector function enhancement: Fc mutations increase binding
• ADCC optimization: Amino acid changes enhance NK cell activation
• Fc silencing: Mutations reduce or eliminate FCGR2A binding
• pH-dependent binding: Engineering for reduced antigen binding at acidic pH

Role in Other Neurodegenerative Diseases

Parkinson's Disease

FCGR2A plays a role in PD through:

• α-Synuclein clearance: Microglial phagocytosis of opsonized α-syn
• Neuroinflammation: Pro-inflammatory cytokine release
• Levodopa-induced dyskinesias: FcγR involvement in inflammatory side effects

Amyotrophic Lateral Sclerosis

In ALS, FCGR2A contributes to:

• Motor neuron inflammation: Activated microglia in spinal cord
• Muscle antibody clearance: FcγR-mediated clearance of autoantibodies
• Disease progression: Correlation with rate of progression

Multiple Sclerosis

FCGR2A modulates MS pathology:

• Demyelination: Antibody-mediated demyelination via FCGR2A
• Therapeutic response: FcγR polymorphisms predict interferon response
• Blood-brain barrier: FcγR involvement in leukocyte trafficking

Experimental Methods

Detection and Quantification

Flow Cytometry

• Surface staining with anti-FCGR2A antibodies
• Quantifies expression levels on different immune cells
• Compares FCGR2A/FCGR2B ratios

• Brain tissue staining reveals regional distribution
• Colocalization with microglial markers (Iba1, CD68)
• Quantifies immune complex deposition

• Detects FCGR2A protein in tissue lysates
• Identifies different splice variants
• Measures phosphorylation states

Functional Assays

Phagocytosis Assays

• Fluorescent bead uptake measures activity
• IgG-opsonized target clearance
• Blockade with FcγR inhibitors

• ELISA measures secreted cytokines
• qPCR for gene expression
• Multiplex assays for cytokine panels

Therapeutic Strategies

Currently in Development

Small Molecule Inhibitors

• Syk inhibitors (fostamatinib, entospletinib)
• PI3Kδ inhibitors (idelalisib derivatives)
• BTK inhibitors (ibrutinib effects on FcγR)

• Anti-FCGR2A antibodies for blocking
• FCGR2B agonists for inhibition
• Soluble FcγR decoys

Gene Therapy Approaches

• CRISPR editing of FCGR2A/FCGR2B balance
• Viral vector delivery of inhibitory receptors
• RNA interference for knockdown

Biomarker Potential

Diagnostic Applications

CSF Biomarkers

• Soluble FCGR2A in cerebrospinal fluid
• Correlates with disease severity
• Distinguishes AD from other dementias

• PET ligands for microglial activation
• TSPO vs. FCGR2A-specific approaches
• In vivo visualization of inflammation

Prognostic Applications

Clinical Outcomes

• FCGR2A expression predicts progression rate
• Genetic variants modify therapeutic response
• Stratification for clinical trials

Cross-species Comparison

Murine Orthologs

Mouse has multiple FCGR2A orthologs:

• FcγRIIB (CD32B): Inhibitory, equivalent to human FCGR2B
• FcγRIII (CD16): Activating receptor
• Different cell type expression: Caution in translating findings

Zebrafish Models

Zebrafish provide insights into:

• Developmental phagocyte function
• Inflammation resolution mechanisms
• Conservation of FcγR signaling

Future Research Directions

Critical Questions

Emerging Areas

• Single-cell sequencing: Defining microglial subpopulations
• Spatial transcriptomics: Regional FCGR2A expression patterns
• CRISPR screening: Identifying genetic modifiers

Conclusion

FCGR2A represents a critical nexus between humoral immunity and neuroinflammation in neurodegenerative diseases. Its dual role in both beneficial amyloid clearance and pathological inflammation presents a therapeutic challenge. Understanding the precise mechanisms governing FCGR2A function in microglia offers opportunities for developing targeted therapies that maintain beneficial phagocytosis while limiting inflammatory neurodegeneration.

References